
Background Existing surgical risk prediction tools are often limited by short-term outcomes. Our study aimed to develop and validate perioperative models and preoperative models for predicting mortality and major complications using surgical data from Hong Kong. Methods This population-based retrospective cohort study analysed 11 years of surgical data (July 2014–June 2024) collected from 17 public hospitals in Hong Kong. Of 124 clinically relevant candidate predictors, 67 predictors were retained for the perioperative full models. To improve clinical usability and facilitate preoperative risk assessment, reduced preoperative models were trained using 13 predictors. Separate models were developed for emergency and elective surgery. Primary outcomes were 30-day, 60-day, and 90-day all-cause mortality in emergency and elective surgery cohorts. Secondary outcomes included 30-day major surgical-related and medical-related complications. Multiple risk prediction models were evaluated using training data from 2014 to 2021 with 5-fold stratified cross-validation, while temporal external validation was performed using data from 2022 to 2024. Performance was assessed using the area under the receiver operating characteristic curve (AUROC), area under the precision–recall curve (AUPRC), Brier score, calibration intercept and slope, integrated calibration index (ICI), E50, and E90. SHAP was used for model interpretation. Models showing poor calibration underwent logistic recalibration using five-fold out-of-fold development predictions. Findings 43,601 subjects were included in the training set and 16,143 in the external validation set for emergency surgeries, whereas 151,016 subjects were used for training and 37,586 for external validation for elective surgeries. In temporal validation, the perioperative full models achieved AUROCs of 0.89, 0.89, and 0.89 for 30-day, 60-day, and 90-day mortality after emergency surgery and 0.91, 0.90, and 0.90 after elective surgery. Corresponding AUPRCs were 0.27, 0.36, and 0.41 for emergency surgery and 0.05, 0.10, and 0.13 for elective surgery. AUROCs for medical- and surgery-related complications were 0.88 and 0.78 in emergency surgery and 0.87 and 0.80 in elective surgery. The 13-predictor preoperative models retained useful discrimination, although performance was lower than that of the perioperative full models. Calibration assessment indicated variable agreement between predicted and observed risks, supporting the need for recalibration before clinical implementation. Eight complication-specific models showed validation AUROCs ranging from 0.75 to 0.94. SHAP analysis revealed clinically plausible risk factors, such as higher ASA status, abnormal laboratory results (such as renal dysfunction and low albumin), and surgical complexity. Logistic recalibration improved Brier scores and calibration indices across all full and reduced models without changing AUROC or AUPRC. Interpretation We have developed and validated comprehensive surgical risk prediction models with excellent discrimination and robust performance using 11 years of population-based data from Hong Kong. The identified predictors were clinically interpretable, which can serve as a data-driven tool to assist clinicians and patients for surgical risk assessments. Funding Health and Medical Research Fund (21220531) and National Natural Science Foundation of China (72574190).
Background Closing the tuberculosis (TB) diagnostic gap requires accessible non-sputum-based point-of-care testing. The Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM I) assay was a promising tool but showed lot-to-lot variability. Following a redesign, we evaluated the second-generation assay (FujiLAM II) in people living with HIV (PLHIV) and HIV-negative individuals, across varying care settings. Methods We combined two prospective multicentre studies in Vietnam, recruiting adults with presumptive TB identified through facility- and community-based screening. Participants gave urine for FujiLAM II testing and sputum specimens for testing with the Xpert MTB/RIF Ultra assay (Xpert–Ultra) and, in one study, mycobacterial culture. We calculated sensitivity and specificity of FujiLAM II against culture and a microbiological reference standard (MRS), defined as positivity on culture and/or Xpert–Ultra. Findings Among 3087 participants, 563 (18.2%) had TB by MRS and 684 (22.2%) were PLHIV. Against culture, sensitivity of FujiLAM II was 30.5% (95% CI 25.8–35.6%) and specificity 99.3% (95% CI 98.8–99.6%); against MRS, sensitivity was 29.5% (95% CI 25.7–33.4%) and specificity 99.3% (95% CI 98.9–99.6%). Culture-based sensitivity was lower during community-based screening, compared with facility-based screening (10.5%, 95% CI 1.3–33.1% versus 31.6%, 95% CI 26.7–36.9%). MRS-based sensitivity of the test was higher among PLHIV (52.9%, 95% CI 38.5–67.1) than HIV-negative (27.1%, 95% CI 23.3–31.2), especially with CD4 < 200 cells/μL (78.9%, 95% CI 54.4–93.9%). Interpretation FujiLAM II exhibited high specificity but limited sensitivity. Sensitivity was highest among PLHIV with advanced immunosuppression and remained low in HIV-negative individuals and during community-based screening. These findings align with WHO recommendations for targeted urine-LAM use. Funding The Stop TB Partnership’s TB REACH initiative, with funds from Global Affairs Canada; Unitaid; Fujifilm (in-kind donation of tests).
Poor diet quality is a leading driver of noncommunicable diseases (NCDs) and growing health and economic burden across the Western Pacific region, yet nutrition remains under-integrated within healthcare systems. Food is Medicine (FIM) programs — defined as integration of the provision or subsidisation of healthy food directly into healthcare delivery and financing to prevent or manage diet-sensitive diseases — offer a promising, healthcare-led approach to address diet-related conditions, improve health equity, catalyse local food production, and support transitions towards sustainable food systems. This Viewpoint examines the relevance and potential of FIM in the Western Pacific, summarising core program components and emerging global evidence demonstrating improvements in diet quality, food security, clinical outcomes, and healthcare utilisation. We highlight strong cultural, policy, and healthcare system alignment that may support regional adaptation, alongside potential implementation challenges, including health system constraints, food system vulnerabilities, and limited local evidence. Finally, we propose pragmatic building blocks to guide early-stage design, implementation, and evaluation of FIM programs tailored to diverse regional contexts.